In addition, bsAB targeting CD47 and the B-lymphocyte antigens CD20 (IMM0306) or CD19 (TG-1801) also entered clinical testing for patients with B-cell lymphoma or chronic lymphocytic leukemia (CLL), (NCT04806035, NCT03804996) and B-cell NHL (NCT04746131). This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.